Jun 20, 2022

Rhythm Pharmaceuticals Receives FDA Approval for Drug to Control Obesity in People with Bardet-Biedl Syndrome (BBS)

Eye On the Cure Research News

The newly approved drug reduces the pathologic hunger associated with BBS

Get updates on Eye On the Cure Research News

The US Food & Drug Administration has approved the use of IMICREE® (setmelanotide) for the treatment of chronic obesity associated with Bardet-Biedl syndrome (BBS). Developed by Rhythm Pharmaceuticals, IMICREE is available for BBS patients 6 years of age and older.

BBS is a genetic condition that can cause multiple symptoms including: retinitis pigmentosa; heart, kidney, and liver problems; extra fingers and toes; and weight management challenges due to insatiable hunger. People with BBS may not have all of the associated symptoms. Approximately 1,500-2,500 people in the US have BBS.

In the Phase 3 clinical trial for 31 patients with BBS, mean percent change in body mass index (BMI) was -7.9% at 52 weeks of treatment without requirements for diet and exercise.

IMCIVREE was initially approved by the FDA in November 2020 for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to POMC, PCSK1 or LEPR deficiency.

For more information, visit https://imcivree.com or contact patientsupport@rhythmtx.com.